BRIT produces and supplies a wide range of radiopharmaceuticals to hospitals and medical institutions to enable various diagnostic and therapeutic studies on patients. BRIT Has recently added [177Lu]-Lu-DOTATATE (LUM-3) and [131I]-Lipiodol (IOM 40) as new therapeutic radiopharmaceuticals products.
These radiopharmaceutical products undergo strict quality analysis and quality control tests including sterility, pyrogen tests and biodistribution studies and are manufactured in strict compliance with regulations in India as per the Radiopharmaceutical Committee (RPC) guidelines. AERB Guidelines and regulatory forms for setting up a nuclear medicine facility and seeking authorization/approval for use of radiopharmaceutical products from BRIT are available at AERB website.
177Lu-DOTATATE Injection (Code LUM-3) available in 100 mCi and 200 mCi doses. Production is on fortnightly basis. The product is useful for PRRT of sstr positive Neuroendocrine tumors
131I-Lipiodol Injection (Code IOM 40) available in 75 mCi dose. Production is on a monthly basis. The product is useful in treatment of hepatocellular carcinoma.